Compare
Kesimpta vs. Vumerity

Kesimpta (ofatumumab) is an injectable medication for adults with relapsing forms of multiple sclerosis (MS). It works as a monoclonal antibody to help lessen MS flare-ups that come and go. Kesimpta (ofatumumab) is injected under the skin. You can use the Kesimpta prefilled syringes or Sensoready Pens to inject. After the first 3 weekly injections, you inject the medication once a month. Some common side effects include a higher risk of infections, pain or swelling at the injection site, and headache.

• Relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS, clinically isolated syndrome, and secondary progressive MS

• Upper respiratory tract infections (39%)
• Reactions related to the injection (e.g., fever, chills, tiredness; 21%)
• Headache (13%)
• Reaction at the injection site (e.g., pain, redness, swelling; 11%)
• Urinary tract infection (10%)

• Risk of infections
• Injection reactions
• Lower antibody levels
• Harm to an unborn baby

Vumerity, also known by its generic name dimethyl fumarate, is approved in adults for treating relapsing forms of multiple sclerosis (MS). It belongs to the drug class called fumaric acid derivatives. Vumerity (diroximel fumarate) is a capsule that's taken by mouth twice per day. The most common side effects are stomach upset and flushing (e.g., facial warmth, redness, burning sensation).

• Relapsing forms of multiple sclerosis (MS)

• Flushing (40%)
• Stomach pain (18%)
• Diarrhea (14%)
• Nausea (12%)

• Severe allergic reaction
• Flushing
• Risk for serious infections
• Low white blood cell counts (lymphopenia)
• Liver damage
• Serious stomach and gut problems